Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA

Retrieved on: 2023-12-27 13:01:51

Tags for this article:

Monoclonal antibodies

Biotechnology

Immunology

Antibody-drug conjugates

Antibody-drug conjugate

Bispecific monoclonal antibody

u.s. food and drug administration

Click the tags to see associated articles and topics

Boan Biotech's Two Innovative Drugs Targeting Claudin 18.2 Granted ODD by FDA. View article details on HISWAI: https://en.prnasia.com/releases/apac/boan-biotech-s-two-innovative-drugs-targeting-claudin-18-2-granted-odd-by-fda-432271.shtml

Excerpt

BA1105 is a human anti-Claudin18.2 recombinant IgG1 monoclonal antibody for treating Claudin18.2-positive advanced solid tumors. It is more potent ...

Article found on: en.prnasia.com

View Original Article